Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Faster, Cleaner, Better.

Aveo Pharmaceuticals (AVEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

Cash Flow for [[ item.sessionDateDisplayLong ]]

Fiscal Year End Date: 12/31

(Values in U.S. thousands)

	12-2011	12-2010	12-2009	12-2008	12-2006
Cash Flows From Operating Activities
Net Income	30,648	-58,789	-44,093	-32,473	N/A
Depreciation Amortization	5,455	1,754	1,662	825	N/A
Accounts receivable	-6,819	96	1,594	-1,460	N/A
Accounts payable and accrued liabilities	-343	1,756	3,636	1,437	N/A
Other Working Capital	-16,378	403	29,052	-6,686	N/A
Other Operating Activity	13,888	2,955	-1,824	3,056	0
Operating Cash Flow	$26,451	$-51,825	$-9,973	$-35,301	$N/A

Cash Flows From Investing Activities
Change In Deposits	-141,475	-88,820	5,148	29,507	N/A
PPE Investments	-2,628	-1,686	-1,734	-1,356	N/A
Investing Cash Flow	$-144,103	$-90,506	$3,414	$28,151	$N/A

Cash Flows From Financing Activities
Debt Issued	N/A	7,555	N/A	10,655	N/A
Debt Repayment	N/A	-3,278	-1,986	-3,808	N/A
Common Stock Issued	115,367	138,555	159	34	N/A
Other Financing Activity	0	0	32,862	0	0
Financing Cash Flow	$115,367	$142,832	$31,035	$6,881	$N/A

Beginning Cash Position	45,791	45,290	20,814	21,083	N/A
End Cash Position	43,506	45,791	45,290	20,814	N/A
Net Cash Flow	$-2,285	$501	$24,476	$-269	$N/A

Free Cash Flow
Operating Cash Flow	26,451	-51,825	-9,973	-35,301	N/A
Capital Expenditure	-2,628	-1,686	-1,734	-1,356	N/A
Free Cash Flow	23,823	-53,511	-11,707	-36,657	0